(TVTX) – Press Releases
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
-
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
-
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
-
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Travere Therapeutics to Present at Upcoming Investor Conferences
-
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
-
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
-
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
-
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
-
Travere Therapeutics Provides Corporate Update and 2024 Outlook
-
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
-
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
-
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Ligand Reports Third Quarter 2023 Financial Results
-
Travere Therapeutics Reports Third Quarter 2023 Financial Results
-
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrol
-
Travere Therapeutics to Report Third Quarter 2023 Financial Results
-
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
-
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missi
-
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
-
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
-
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
-
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ligand Reports Second Quarter 2023 Financial Results
-
Travere Therapeutics Reports Second Quarter 2023 Financial Results
-
Travere Therapeutics to Report Second Quarter 2023 Financial Results
-
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
-
Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
-
Travere Therapeutics to Present at Upcoming Investor Conferences
-
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ligand Reports First Quarter 2023 Financial Results
-
Travere Therapeutics Reports First Quarter 2023 Financial Results
-
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
-
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
-
Travere Therapeutics to Report First Quarter 2023 Financial Results
Back to TVTX Stock Lookup
